Lowell Searight, MD
Family Medicine · Hiauatha, KSNPI 1659343671
Payments from drug & device makers
Across 186 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$406
- Amgen$386
- Lilly USA, LLC$341
- AstraZeneca$328
- Boehringer Ingelheim$228
- Johnson & Johnson$175
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,025100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $406 |
| Amgen | 27 | $386 |
| Lilly USA, LLC | 16 | $341 |
| AstraZeneca | 24 | $328 |
| Boehringer Ingelheim | 15 | $228 |
| Johnson & Johnson | 10 | $175 |
| Novartis | 10 | $150 |
| Novo Nordisk | 8 | $108 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $108 |
| Teva Pharmaceuticals USA, Inc. | 4 | $77 |
| Sanofi | 4 | $77 |
| Lundbeck LLC | 4 | $68 |
| E.r. Squibb & Sons, L.L.C. | 5 | $65 |
| Roche Diagnostics Corporation | 3 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $61 |
| Abbott | 3 | $50 |
| Sanofi Pasteur Inc. | 1 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Boston Scientific | 1 | $32 |
| Pfizer | 2 | $29 |
| Viatris Specialty LLC | 2 | $28 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| MDD US Operations, LLC | 1 | $21 |
| Dexcom, Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Bayer | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
How this compares
$3,039 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 123 | $74,944 |
| TrulicityDulaglutide | 49 | $49,181 |
| JardianceEmpagliflozin | 59 | $42,375 |
| MounjaroTirzepatide | 34 | $36,793 |
| XareltoRivaroxaban | 34 | $18,304 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $16,584 |
| Bydureon BciseExenatide Microspheres | 20 | $16,337 |
| JanuviaSitagliptin Phosphate | 16 | $13,598 |
| OzempicSemaglutide | 13 | $12,630 |
| MultaqDronedarone Hcl | 13 | $9,550 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $8,334 |
| SymbicortBudesonide/Formoterol Fumarate | 35 | $8,085 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $6,971 |
| MyrbetriqMirabegron | 15 | $6,728 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 16 | $6,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $341 | $85,97483 claims |
| PfizerEliquis | $29 | $74,944123 claims |
| Boehringer IngelheimJardiance | $228 | $42,37559 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta | $17 | $28,46953 claims |
| Johnson & JohnsonXarelto | $175 | $18,30434 claims |
| Novo NordiskOzempic | $108 | $12,63013 claims |
| AstraZenecaSymbicort | $328 | $8,08535 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $6,72815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Hiauatha
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.